The effect of biosimilar administration on clinical outcomes in patients with adalimumab-controlled psoriasis
{{output}}
Background: Adalimumab is an anti-tumour necrosis factor administered for the management of severe psoriasis. Previously limited to Humira, new biosimilar medications have now emerged including Amgevita. To date, there have been ... ...
